Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FDA Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
Roche’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-symptomatic Babies Under 2 Months of Age with Spinal Muscular Atrophy (SMA)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
CHMP Recommends EU Approval of Actemra/RoActemra to Treat Patients with Severe COVID-19
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration […]
FDA Accepts Application for Roche’s Faricimab for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
New Data for Roche’s Hemlibra Reinforce Safety Profile in People with Haemophilia A
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the […]
Roche’s ENSPRYNG Approved by European Commission as First and Only At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved […]
New Roche Data for Evrysdi Show Improved Motor Function in Pre-symptomatic Babies after One Year
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new interim data from two studies of […]
European Commission Approves Venclyxto-based Combinations for Adults with Newly Diagnosed Acute Myeloid Leukaemia Who Are Ineligible for Intensive Chemotherapy
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto […]
Roche’s Tecentriq Approved by European Commission
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more